Masahiro Ohgami

Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Survey of Pharmaceutical Interventions in Outpatient Cancer Chemotherapy

Survey of Pharmaceutical Interventions in Outpatient Cancer Chemotherapy

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: July 01, 2026

Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report.

Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report.

Journal: Cureus

Published: December 12, 2025

Pharmacokinetic study of erlotinib in a pregnant woman with advanced non-small cell lung cancer and observation of the effects on the child growth.

Pharmacokinetic study of erlotinib in a pregnant woman with advanced non-small cell lung cancer and observation of the effects on the child growth.

Journal: British journal of clinical pharmacology

Published: December 07, 2023

Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report.

Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report.

Journal: Cancer chemotherapy and pharmacology

Published: September 19, 2023

Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial.

Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial.

Journal: Cancer medicine

Published: June 15, 2020

Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.

Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.

Journal: Therapeutic drug monitoring

Published: July 12, 2018

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 29, 2017

A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma.

A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma.

Journal: Therapeutic drug monitoring

Published: November 17, 2016

Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.

Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 21, 2016

Showing 1-9 of 9

Last Updated: 09/26/2026